Curanex Pharmaceuticals Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Curanex Pharmaceuticals Inc. (Nasdaq: CURX) on September 29, 2025, reporting events occurring between September 23 and September 25, 2025. The Company is an emerging growth company incorporated in Nevada.
Key Financial Metrics and Transactions
- Equity Issuance: Issued 28,312 shares of Common Stock to investor Xiaohong Song on September 25, 2025, for $200,000 consideration under a subscription agreement dated November 27, 2024.
- Debt Repayment: Repaid total principal and accrued interest of $408,537.32 on two promissory notes held by Dian Ying Jing (wife of the CEO).
- Debt Elimination: The repayment eliminated all outstanding debt balances and avoided approximately $26,182.68 in future interest charges.
- Capital Structure: Post-issuance, the Company has 28,312,500 total outstanding shares of Common Stock. The new issuance represents 0.1% of total outstanding shares.
Material Changes
The filing details the finalization of post-IPO equity obligations and the complete extinguishment of related-party debt. The Company previously completed its Initial Public Offering (IPO) on August 27, 2025, and exercised the full over-allotment option on September 12, 2025, issuing an aggregate of 4,312,500 shares to underwriters.
Outlook, Risks, and Management Commentary
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of unregistered securities sales. The repayment of the promissory notes was executed without penalty or premium, as permitted by the note terms.
Investor Verification Checklist
- Verify the total outstanding share count of 28,312,500 and the dilution impact of the 28,312 shares issued to Mr. Song.
- Confirm the elimination of the $400,000 related-party debt and the associated interest expense savings.
- Review the Amended and Restated Subscription Agreement with Xiaohong Song for any additional covenants or vesting conditions.
- Assess the Company's current cash position following the $408,537.32 debt repayment and the $200,000 equity raise.